在牛皮关节炎 (AXIS) 项目的轴性参与的更新
Murat Torgutalp1, Denis Poddubnyy2, Dafna D Gladman3
1M. Torgutalp, MD, MSc, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, Germany.
The Journal of rheumatology
|August 5, 2025
概括
牛皮关节炎 (PsA) 轴参与在一项大型国际研究中进行了评估. 超过27%的牛皮关节炎患者表现出轴性症状,影响脊柱和关节.
科学领域:
- 类风湿病学 类风湿病学
- 炎症性疾病 炎症性疾病
- 脊椎关节炎是一种脊柱性关节炎.
背景情况:
- 牛皮关节炎 (PsA) 是一种与牛皮相关的慢性炎症状况.
- 在PsA患者中,轴性骨架结构 (脊椎和关节) 经常受到影响.
- 需要一个统一的定义和对PsA轴参与的分类.
研究的目的:
- 建立PSA轴参与的统一定义和分类标准.
- 评估在多国PSA队列中轴性干涉的流行程度.
主要方法:
- 在牛皮关节炎 (AXIS) 的轴性参与研究中,在19个国家的41个中心招募了409名患者.
- 对关节和脊椎进行了全面的临床和成像评估 (X射线图,MRI).
- 数据由当地调查人员和中央成像委员会审查,以进行最终评估.
主要成果:
- 在409名患者中,有112名患者 (27.4%) 确诊了轴性参与.
- 数据分析正在进行中,预计将很快得到完整的结果.
- 初步调查结果在GRAPPA 2024年会上进行了介绍.
结论:
- 轴性干涉是PsA患者中相当一部分患者的重要特征.
- AXIS研究提供了关键数据,用于制定轴性PSA的标准化标准.
- 进一步的分析将完善对PsA轴性疾病的理解和分类.
相关概念视频
Genome-wide Association Studies-GWAS
14.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.2K
Development of the Limb Synovial Joints
1.6K
Joints form during embryonic development in conjunction with the formation and growth of the associated bones. The embryonic tissue that gives rise to all bones, cartilage, and connective tissues of the body is called mesenchyme.
The mesenchymal stem cells differentiate into chondrocytes that form the hyaline cartilage, and later the cartilaginous model of the bone. This model further transforms into a bone. This process is known as endochondral ossification.
During development, the limbs...
The mesenchymal stem cells differentiate into chondrocytes that form the hyaline cartilage, and later the cartilaginous model of the bone. This model further transforms into a bone. This process is known as endochondral ossification.
During development, the limbs...
1.6K
Peripheral Artery Disease I: Introduction
33
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
33
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35


